Related references
Note: Only part of the references are listed.Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
Peter Gross et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Vicente E. Torres et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care
Tess Harris et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
274 Impact of Tolvaptan on Costs Associated with Renal Pain and Chronic Kidney Disease Among Patients with Autosomal Dominant Polycystic Kidney Disease
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
Yashang Lee et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
REPRISE: tolvaptan in advanced polycystic kidney disease
Christina M. Wyatt et al.
KIDNEY INTERNATIONAL (2018)
FP047POTENTIAL IMPACT OF TOLVAPTAN ON BLOOD PRESSURE IN THE TEMPO 3:4 PATIENT POPULATION
Arlene Chapman et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
FP052EFFECTIVENESS AND SAFETY OF TOLVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS WITH CKD STAGE G4: A RETROSPECTIVE MULTICENTER STUDY IN JAPAN
Kazunori Yamada et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
SP027EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE STAGE CKD
Fumihiko Hattanda et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
SP110EFFECT OF TOLVAPTAN ON RENAL PLASMA FLOW AND GLOMERULAR FILTRATION IN POLYCYSTIC KIDNEY DISEASE
My Malmberg et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
FP061A PROSPECTIVE STUDY OF THE EFFICACY AND ADVERSE EFFECTS OF TOLVAPTAN FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Hirayasu Kai et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Fouad T. Chebib et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
Masahiko Oguro et al.
JOURNAL OF NEPHROLOGY (2018)
Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study
Satoshi Minami et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors
Jeffrey L. Woodhead et al.
TOXICOLOGICAL SCIENCES (2017)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study
Safa Al Therwani et al.
BMC NEPHROLOGY (2017)
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3: 4
Olivier Devuyst et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Polycystic Kidney Disease and the Vasopressin Pathway
Maatje D. A. van Gastel et al.
ANNALS OF NUTRITION AND METABOLISM (2017)
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
Niek F. Casteleijn et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Ron T. Gansevoort et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Autosomal dominant polycystic kidney disease
Roslyn J. Simms
BMJ-BRITISH MEDICAL JOURNAL (2016)
Autosomal dominant polycystic kidney disease
Roslyn J. Simms
BMJ-BRITISH MEDICAL JOURNAL (2016)
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3: 4 Clinical Trial
Maria V. Irazabal et al.
KIDNEY INTERNATIONAL REPORTS (2016)
Clinical Manifestation and Management of ADPKD in Western Countries
Claudia Sommerer et al.
KIDNEY DISEASES (2016)
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
Wendy E. Boertien et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial
Satoru Muto et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan
Laura R. Harskamp et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
Hannah A. Blair et al.
DRUGS (2015)
Exploring urinary biomarkers in autosomal dominant polycystic kidney disease
Haruna Kawano et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
Susan E. Shoaf et al.
KIDNEY INTERNATIONAL (2014)
Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury
Miki Aihara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
Wendy E. Boertien et al.
KIDNEY INTERNATIONAL (2013)
Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects
Susan E. Shoaf et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects
Ming-Yang Chang et al.
NEPHRON CLINICAL PRACTICE (2012)
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
Maria V. Irazabal et al.
KIDNEY INTERNATIONAL (2011)
Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug
E. Meijer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
Gail A. Reif et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, 1498 a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects
Susan E. Shoaf et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Share Paper
